Sarepta Therapeutics Stock Plummets After Q1 Results: Here's Why

Sarepta Therapeutics, Inc. SRPT shares are sinking after the company released its first-quarter results after Tuesday's closing bell. Here's a look at the details from the report. 

The Details: Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. Quarterly revenue came in at $744.86 million, which beat the consensus estimate of $683.36 million.

Read Next:  President Trump Wants To Reopen Alcatraz: Here’s What It Would Take

“In the first quarter, we achieved net product revenue of $611.5 million, a 70% increase over the same quarter prior year; our PMO franchise performed well at $236.5 million; and ELEVIDYS achieved $375 million, growing at 180% over the same quarter prior year. However, we also faced headwinds in the quarter. While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion,” said Doug Ingram, CEO of Sarepta Therapeutics. 

Outlook: Sarepta Therapeutics lowered its fiscal 2025 revenue to a new range of $2.3 billion to $2.6 billion.

SRPT Price Action: According to data from Benzinga Pro, Sarepta Therapeutics stock was down 23.21% at $35.90 after-hours after falling 26.56% during regular trading on Tuesday.  

Read Next: 

• Upwork Delivers ‘Solid Start To 2025’: Analyst 

Image: Shutterstock